

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

**PARTIAL REPURCHASE AND CANCELLATION OF US\$280 MILLION
1.00 PER CENT GUARANTEED CONVERTIBLE BONDS DUE 2025
ON THE OPEN MARKET
(STOCK CODE: 40514)**

References are made to the announcements (the “**Announcements**”) of Viva Biotech Holdings (the “**Company**”) dated December 18, 2020 and December 30, 2020 regarding the issuance of the US\$280 million 1.00 per cent guaranteed convertible bonds by Viva Biotech Investment Management Limited (a wholly-owned subsidiary of the Company) due 2025 (the “**Convertible Bonds**”) and the announcements of the Company dated July 31, 2022, October 13, 2023 and November 20, 2023 regarding the partial repurchase and cancellation of the Convertible Bonds. Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Announcements.

The Company hereby announces that it has completed the repurchase of Convertible Bonds in the principal amount of US\$34,100,000 on the date of this announcement, and the aggregate principal amount of the Convertible Bonds repurchased has increased to of US\$143,400,000 (the “**Repurchased Convertible Bonds**”). The Repurchased Convertible Bonds has the rights to be converted into 95,524,831 shares of the Company, and represents approximately 51.21% of the aggregate principal amount of the Convertible Bonds originally issued. The Board considered that there will be no material impact on the financial position of the Company as a result of the aforesaid repurchase of the Repurchased Convertible Bonds. The Board believes that the repurchase and subsequent cancellation of the Repurchased Convertible Bonds reflects the Company’s confidence in its long-term business prospects and could also enhance the return to the shareholders of the Company.

The Company expects to cancel the Repurchased Convertible Bonds as soon as possible. Immediately after the cancellation, an aggregate principal amount of US\$136,600,000 of the Convertible Bonds will remain outstanding.

Pursuant to Rule 37.48(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company will make a further announcement for every subsequent 5% interval of the initial aggregate principal amount of the Convertible Bonds that have been redeemed or cancelled in accordance with the terms and conditions of the Convertible Bonds.

Holders of the Convertible Bonds and other securities of the Company as well as potential investors should exercise caution when dealing in securities of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, November 27, 2023

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.